|display ongoing studies|
|Study||Ref.||Design||studied treatment||control treatment||patients||study risk of bias||sample sizes||Results|
COVID-19 prophylaxis (excluding children) meta-analysis
|BLAZE-2 US (Cohen)|
|RCT||bamlanivimab monotherapy||placebo||COVID-19 prophylaxis (excluding children)||some concern||588/587||conclusif|
PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).